

CONSOLIDATED DEVELOPMENT PIPELINE BY PHASE



	PHASE 3 (7 NMEs + 25 LCMs)				FILED (1 NMEs + 7 LCMs)	
ONCOLOGY	<p>★ EXKIVITY[®] 1L NSCLC EGFR exon 20</p> <p>★ NINLARO[®] Maint. ND MM no SCT (US, EU, CN)</p>	<p>ICLUSIG[®] 1L Ph+ ALL (US)</p> <p>★ NINLARO[®] Maint. ND MM post-SCT (US, EU)</p>	<p>CABOMETYX[®] mCRPC combo w/atezolizumab (JP)</p> <p>ZEJULA[®] Breast cancer (JP)</p>	<p>CABOMETYX[®] 2L mNSCLC combo w/atezolizumab (JP)</p> <p>relugolix Prostate cancer (JP, CN)</p>		
RARE GENETICS & HEMATOLOGY	<p>★ TAK-755 cTTP</p> <p>★ TAKHZYRO[®] Pediatric HAE (EU)</p>	<p>★ pabinafusp alfa Hunter Syndrome</p> <p>★ TAKHZYRO[®] BMA</p>	<p>★ LIVTENCITY[®] 1L CMV infect. in HSCT</p> <p>★ VONVENDI[®] vWD Adult Prophylaxis (EU, CN)</p>	<p>★ LIVTENCITY[®] Post-transplant CMV infect. (JP)</p> <p>★ VONVENDI[®] vWD peds on-demand & surgery</p>	<p>★ OBIZUR[®] Recomb antihemophilic factor porcine (JP)</p> <p>ADYNOVATE[®] recombinant Factor VIII Pediatric Hema (EU)</p>	<p>OBIZUR[®] Recomb antihemophilic factor porcine (CN)</p> <p>★ TAKHZYRO[®] Pediatric HAE (US)</p>
NEUROSCIENCE	<p>★ soticlestat DS</p>	<p>★ soticlestat LGS</p>				
GASTRO-ENTEROLOGY	<p>ENTYVIO[®] SC CD (US, JP)</p> <p>ENTYVIO[®] Pediatric UC</p>	<p>ENTYVIO[®] SC UC (US)¹</p> <p>ENTYVIO[®] Pediatric CD</p>	<p>★ ALOFISEL[®] Perianal Fistulas in CD (US)</p> <p>★ ENTYVIO[®] GvHD Prophylaxis</p>	<p>★ ALOFISEL[®] Pediatric perianal Fistulas in CD</p>		<p>ENTYVIO[®] SC UC (JP)</p> <p>VOCINTI[®] <i>H. Pylori</i> (CN)</p>
PDT	<p>★ HYQVIA[®] CIDP (US, EU)</p> <p>TAK-880 IgG – Low IgA</p>	<p>★ HYQVIA[®] CIDP, MMN (JP)</p> <p>Prothromplex DOAC Reversal (US)</p>	<p>HYQVIA[®] PID (JP)</p>		<p>HYQVIA[®] HyHub AVA Device (US)</p> <p>★ HYQVIA[®] Pediatric PID (US)</p>	<p>CUVITRU[®] PID, SID (JP)</p>
VACCINES	<p>Nuvaxovid[®] COVID-19 Vaccine Booster (JP)</p>	<p>TAK-003 Dengue Vaccine Booster</p>			<p>QDENG² Dengue Vaccine (EU + endemic countries)</p>	

1. Currently undergoing development after receiving FDA CRL in 2019

2. QDENG is the brand name of TAK-003 in Indonesia

★ Orphan Drug Designation potential (in any region / indication for a given asset)



All timelines are approximate estimates as of October 27, 2022, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

CONSOLIDATED DEVELOPMENT PIPELINE BY PHASE



	PHASE 1 (20 NMEs + 1 LCMs)					PHASE 2 (14 NMEs + 2 LCMs)				
ONCOLOGY	TAK-102 Solid tumors	TAK-103 Solid tumors	TAK-186 EGFR Solid Tumor ¹	TAK-940 CD19+ hematologic malignancies	★ modakafusp alfa Solid tumors	★ modakafusp alfa R/R MM	★ subasumstat Multiple cancers	★ TAK-007 CD19+ hematologic malignancies		
	TAK-500 Solid tumors	TAK-676 Solid tumors	TAK-280 B7-H3 Solid Tumor ¹	ICLUSIG® Pediatric Ph+ ALL						
RARE GENETICS & HEMATOLOGY	★ TAK-755 SCD	★ mezagitamab IgAN ²				★ mezagitamab MG	★ mezagitamab ITP	★ TAK-611 MLD (IT)	★ TAK-755 iTTP	
NEUROSCIENCE	★ TAK-861 NT1	TAK-341 Parkinson's Disease	★ TAK-925 Post-anesthesia	★ TAK-594 Frontotemporal dementia ¹	TAK-920 Alzheimer's Disease NEW	TAK-071 Parkinson's Disease	TAK-041 Anhedonia in MDD	TAK-653 Inadequate resp. in MDD		
GASTRO-ENTEROLOGY	TAK-510 Nausea & vomiting	TAK-105 Nausea & vomiting	sibofimloc Luminal Crohn's Disease			TAK-101 Celiac Disease	TAK-954 POGD	★ fazirsiran AATD-Associated Liver Disease	TAK-951 Nausea & vomiting	
						★ TAK-227 Celiac Disease NEW	TAK-062 Celiac Disease ²	sibofimloc Crohn's Disease (Post-op Ileitis)		
PDT						CEPROTIN® SC PCD (JP)	TAK-881 Immunodeficiencies			
VACCINES	TAK-426 Zika Vaccine									

1. Currently in phase 1 of a phase 1/2 trial
2. Study actively recruiting

NEW Added to clinical development since last quarter
★ Orphan Drug Designation potential (in any region / indication for a given asset)



All timelines are approximate estimates as of October 27, 2022, are subject to change and are subject to clinical and regulatory success. Table is not comprehensive. For full glossary of abbreviations please refer to appendix.

GLOSSARY OF ABBREVIATIONS



Regional Abbreviations:

CN: China; EU: Europe; JP: Japan; US: United States of America

AATD	α1-antitrypsin deficiency
ADC	antibody drug conjugate
ADHD	attention deficit hyperactivity disorder
AHA	acquired hemophilia A
ALK	anaplastic lymphoma kinase
ALCL	anaplastic large-cell lymphoma
ALL	acute lymphocytic leukemia
AML	acute myeloid leukemia
ASCT	autologous stem cell transplant
ARD	acid-related diseases
AVA	Advanced Vial Access
BBB	blood brain barrier
BLA	biologics license application
BMA	bradykinin mediated angioedema
BTD	breakthrough therapy designation
CAR-T	chimeric antigen receptor-T
CD	Crohn's disease
CHMP	Committee for Medicinal Products for Human Use
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy
CLL	chronic lymphocytic leukemia
CML	chronic myeloid leukemia
CMV	cytomegalovirus
CNS	central nervous system
CPF	complex perianal fistulas
CRL	complete response letter
CRPC	Castrate-resistant prostate cancer
CTCL	cutaneous T-cell lymphoma
cTTP	congenital thrombotic thrombocytopenic purpura
DEE	developmental and epileptic encephalopathies
DLBCL	diffuse large B-cell lymphoma
DOAC	direct oral anti-coagulation

DS	Dravet syndrome
DU	duodenal ulcer
Dx	Diagnosis
EE H	erosive esophagitis healing
EE M	erosive esophagitis maintenance
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
FDA	the U.S. Food & Drug Administration
FL	front line
FSI	first subject in
FY	fiscal year
GERD	gastroesophageal reflux disease
GI	gastrointestinal
GU	gastric ulcer
GvHD	graft versus host disease
HAE	hereditary angioedema
H2H	head-to-head
HemA	hemophilia A
HL	Hodgkin lymphoma
HSCT	hematopoietic stem cell transplant
IBD	inflammatory bowel disease
IgAN	immunoglobulin A nephropathy
IH	idiopathic hypersomnia
INCAT	Inflammatory Neuropathy Cause and Treatment disability score
IND	investigational new drug
INHL	indolent non-Hodgkin's lymphoma
ITP	Immune thrombocytopenic purpura
iTTP	immune thrombotic thrombocytopenic purpura
IV	intravenous
iPSC	induced pluripotent stem cells
L-ASA	low dose aspirin
LSD	lysosomal storage disorder

LCM	lifecycle management
LGS	Lennox-Gastaut syndrome
mAb	monoclonal antibody
MAOB	monoamine oxidase B
MDD	major depressive disorder
MG	myasthenia gravis
MLD	metachromatic leukodystrophy
MM	multiple myeloma
MMN	multifocal motor neuropathy
NBE	New Biological Entity
NCE	New Chemical Entity
ND	newly diagnosed
NDA	new drug application
Neg	Negative
NERD	non-erosive reflux disease
NHL	non-Hodgkin lymphoma
NK	natural killer
NME	new molecular entity
NMPA	National Medical Products Administration
NSCLC	non-small cell lung cancer
NSCT	non stem cell transplant
NT1 or 2	narcolepsy Type 1 or 2
ORR	overall response rate
OSA	obstructive sleep apnea
PARP	poly (ADP-ribose) polymerase
PAS	prior approval supplement
PCAB	potassium competitive acid blocker
PCD	protein C deficiency
PEX	plasma exchange
Ph+ ALL	Philadelphia chromosome-positive acute lymphoblastic leukemia
PID	primary immunodeficiency

PK	pharmacokinetics
PMDA	Japan's Pharmaceuticals and Medical Devices Agency
POC	proof of concept
POGD	post-operative gastrointestinal dysfunction
PONV	postoperative nausea and vomiting
PRIME	Priority medicines scheme by EMA
PTCL	peripheral T-cell lymphoma
PTH	parathyroid hormone
R/R	relapsed/refractory
RCC	renal cell cancer
RTK	receptor tyrosine kinase
RTU	ready to use
sALCL	systemic anaplastic large cell lymphoma
SBS	short bowel syndrome
SC	subcutaneous formulation
SCD	sickle cell disease
SCT	stem cell transplant
SID	secondary immunodeficiency
SLE	systemic lupus erythematosus
sq	squamous
STING	stimulator of interferon genes
SUMO	small ubiquitin-related modifier
TCE	T-cell engager
TESD	treatment emergent sexual dysfunction
TKI	tyrosine kinase inhibitor
TREM2	triggering receptor expressed on myeloid cells 2
UC	ulcerative colitis
VCD	virologically confirmed dengue
vWD	von Willebrand disease
VWF	von Willebrand factor